CH622426A5 - Contraceptive composition - Google Patents
Contraceptive composition Download PDFInfo
- Publication number
- CH622426A5 CH622426A5 CH604874A CH604874A CH622426A5 CH 622426 A5 CH622426 A5 CH 622426A5 CH 604874 A CH604874 A CH 604874A CH 604874 A CH604874 A CH 604874A CH 622426 A5 CH622426 A5 CH 622426A5
- Authority
- CH
- Switzerland
- Prior art keywords
- pro
- ser
- hcg
- peptide
- immunization
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title description 17
- 239000003433 contraceptive agent Substances 0.000 title description 3
- 230000002254 contraceptive effect Effects 0.000 title description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 89
- 229940088597 hormone Drugs 0.000 description 78
- 239000005556 hormone Substances 0.000 description 78
- 229940040129 luteinizing hormone Drugs 0.000 description 68
- 102000009151 Luteinizing Hormone Human genes 0.000 description 67
- 108010073521 Luteinizing Hormone Proteins 0.000 description 67
- 230000003053 immunization Effects 0.000 description 57
- 238000002649 immunization Methods 0.000 description 55
- 102000004196 processed proteins & peptides Human genes 0.000 description 42
- 239000000243 solution Substances 0.000 description 41
- 241001465754 Metazoa Species 0.000 description 35
- 235000018102 proteins Nutrition 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 32
- 238000000034 method Methods 0.000 description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- 239000000427 antigen Substances 0.000 description 25
- 102000036639 antigens Human genes 0.000 description 25
- 108091007433 antigens Proteins 0.000 description 25
- 210000002966 serum Anatomy 0.000 description 25
- 241001504519 Papio ursinus Species 0.000 description 24
- 238000002347 injection Methods 0.000 description 24
- 239000007924 injection Substances 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 21
- 241000282414 Homo sapiens Species 0.000 description 19
- 230000004048 modification Effects 0.000 description 19
- 238000012986 modification Methods 0.000 description 19
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 16
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 229940028334 follicle stimulating hormone Drugs 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- 229920001917 Ficoll Polymers 0.000 description 15
- 239000003607 modifier Substances 0.000 description 15
- 230000016087 ovulation Effects 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 14
- 230000008878 coupling Effects 0.000 description 13
- 238000010168 coupling process Methods 0.000 description 13
- 238000005859 coupling reaction Methods 0.000 description 13
- 235000002639 sodium chloride Nutrition 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 230000027758 ovulation cycle Effects 0.000 description 12
- 210000002700 urine Anatomy 0.000 description 12
- 241000282520 Papio Species 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 235000000346 sugar Nutrition 0.000 description 11
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 10
- 108091005601 modified peptides Proteins 0.000 description 10
- 230000001850 reproductive effect Effects 0.000 description 10
- 230000011599 ovarian follicle development Effects 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 229940011871 estrogen Drugs 0.000 description 8
- 239000000262 estrogen Substances 0.000 description 8
- 238000002523 gelfiltration Methods 0.000 description 8
- 239000000583 progesterone congener Substances 0.000 description 8
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 241000282693 Cercopithecidae Species 0.000 description 7
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 125000003277 amino group Chemical group 0.000 description 7
- 230000009260 cross reactivity Effects 0.000 description 7
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 7
- 229960003399 estrone Drugs 0.000 description 7
- 230000001900 immune effect Effects 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 150000008163 sugars Chemical class 0.000 description 7
- 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 6
- 229920002307 Dextran Polymers 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 6
- 230000029849 luteinization Effects 0.000 description 6
- 210000002826 placenta Anatomy 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 5
- 102000006771 Gonadotropins Human genes 0.000 description 5
- 108010086677 Gonadotropins Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 108010071390 Serum Albumin Proteins 0.000 description 5
- 102000007562 Serum Albumin Human genes 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 239000002622 gonadotropin Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 230000001817 pituitary effect Effects 0.000 description 5
- 108010033949 polytyrosine Proteins 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 101000895818 Homo sapiens Chorionic somatomammotropin hormone 1 Proteins 0.000 description 4
- 101000956228 Homo sapiens Chorionic somatomammotropin hormone 2 Proteins 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000001588 bifunctional effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- -1 cyanuric acid halide Chemical class 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 229930182833 estradiol Natural products 0.000 description 4
- 229960005309 estradiol Drugs 0.000 description 4
- 230000035558 fertility Effects 0.000 description 4
- 108010074605 gamma-Globulins Proteins 0.000 description 4
- 230000003054 hormonal effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000005906 menstruation Effects 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- 101000687438 Homo sapiens Prolactin Proteins 0.000 description 3
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 description 3
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 description 3
- 206010062767 Hypophysitis Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 210000003635 pituitary gland Anatomy 0.000 description 3
- 108010054442 polyalanine Proteins 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 230000027272 reproductive process Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229950000244 sulfanilic acid Drugs 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- ZKZNWRUUTQNYTH-UHFFFAOYSA-N 4-azidobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(N=[N+]=[N-])C=C1 ZKZNWRUUTQNYTH-UHFFFAOYSA-N 0.000 description 2
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010024769 Local reaction Diseases 0.000 description 2
- 108010003044 Placental Lactogen Proteins 0.000 description 2
- 239000000381 Placental Lactogen Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000006193 diazotization reaction Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940094892 gonadotropins Drugs 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 108060003552 hemocyanin Proteins 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- KQSSATDQUYCRGS-UHFFFAOYSA-N methyl glycinate Chemical compound COC(=O)CN KQSSATDQUYCRGS-UHFFFAOYSA-N 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000000863 peptide conjugate Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000002516 postimmunization Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- CJNZAXGUTKBIHP-UHFFFAOYSA-N 2-iodobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I CJNZAXGUTKBIHP-UHFFFAOYSA-N 0.000 description 1
- 102220600408 Alpha-lactalbumin_I12S_mutation Human genes 0.000 description 1
- 241001135755 Betaproteobacteria Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- VTJUNIYRYIAIHF-IUCAKERBSA-N Leu-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O VTJUNIYRYIAIHF-IUCAKERBSA-N 0.000 description 1
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 206010033157 Ovarian enlargement Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 101800005164 Peptide V Proteins 0.000 description 1
- 102000013469 Placental Hormones Human genes 0.000 description 1
- 108010065857 Placental Hormones Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- IFMDQWDAJUMMJC-DCAQKATOSA-N Pro-Ala-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O IFMDQWDAJUMMJC-DCAQKATOSA-N 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 206010042573 Superovulation Diseases 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- IBIDRSSEHFLGSD-YUMQZZPRSA-N Val-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-YUMQZZPRSA-N 0.000 description 1
- 241000458243 Viana Species 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000002532 anti-gammaglobulin Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000006149 azo coupling reaction Methods 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000000431 corpus luteum hormone Substances 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- RZVGUUMNWCDIBV-UHFFFAOYSA-N diethyl propanediimidate Chemical compound CCOC(=N)CC(=N)OCC RZVGUUMNWCDIBV-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- ZLFRJHOBQVVTOJ-UHFFFAOYSA-N dimethyl hexanediimidate Chemical compound COC(=N)CCCCC(=N)OC ZLFRJHOBQVVTOJ-UHFFFAOYSA-N 0.000 description 1
- FRTGEIHSCHXMTI-UHFFFAOYSA-N dimethyl octanediimidate Chemical compound COC(=N)CCCCCCC(=N)OC FRTGEIHSCHXMTI-UHFFFAOYSA-N 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 239000003933 gonadotropin antagonist Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 229940124452 immunizing agent Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011545 laboratory measurement Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- IFPHDUVGLXEIOQ-UHFFFAOYSA-N ortho-iodosylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I=O IFPHDUVGLXEIOQ-UHFFFAOYSA-N 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000002281 placental hormone Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229950002929 trinitrophenol Drugs 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- IBIDRSSEHFLGSD-UHFFFAOYSA-N valinyl-arginine Natural products CC(C)C(N)C(=O)NC(C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/5555—Muramyl dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35789273A | 1973-05-07 | 1973-05-07 | |
| US40682173A | 1973-10-16 | 1973-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH622426A5 true CH622426A5 (en) | 1981-04-15 |
Family
ID=26999834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH604874A CH622426A5 (en) | 1973-05-07 | 1974-05-03 | Contraceptive composition |
Country Status (17)
| Country | Link |
|---|---|
| JP (1) | JPS623128B2 (xx) |
| AT (1) | AT356263B (xx) |
| AU (1) | AU524925B2 (xx) |
| CA (1) | CA1057742A (xx) |
| CH (1) | CH622426A5 (xx) |
| DD (1) | DD113919A5 (xx) |
| DE (1) | DE2421943A1 (xx) |
| FR (1) | FR2228477B1 (xx) |
| GB (1) | GB1473601A (xx) |
| HK (1) | HK41280A (xx) |
| IE (1) | IE42002B1 (xx) |
| IL (1) | IL44779A (xx) |
| MY (1) | MY8100128A (xx) |
| NL (1) | NL7406098A (xx) |
| NZ (1) | NZ174192A (xx) |
| PL (1) | PL97318B1 (xx) |
| SE (1) | SE7406096L (xx) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526716A (en) * | 1981-11-20 | 1985-07-02 | The Ohio State University | Antigenic modification of polypeptides |
| CA1054937A (en) * | 1975-01-28 | 1979-05-22 | Gursaran P. Talwar | Antipregnancy vaccine |
| FR2319379A1 (fr) * | 1975-07-29 | 1977-02-25 | All India Inst Medical Scie | Vaccin contre la gravidite et procede de sa preparation |
| JPS55160725A (en) * | 1975-07-30 | 1980-12-13 | Paashiyado Taruwaa Gaasaran | Contraceptive vaccine and its manufacture |
| NZ182272A (en) * | 1975-10-14 | 1985-03-20 | Univ Ohio State | Modified polypeptides for the immunological control of fertility,and pharmaceutical compositions |
| JPS5294416A (en) * | 1976-01-24 | 1977-08-09 | Paashiyado Taruwaa Gaasaran | Vaccine for contraception and use of same |
| JPS5633907Y2 (xx) * | 1976-09-16 | 1981-08-11 | ||
| US4096237A (en) * | 1977-03-14 | 1978-06-20 | Hoffmann-La Roche Inc. | Immunoassay for β-endorphin |
| US4234561A (en) * | 1978-02-06 | 1980-11-18 | Research Corporation | Antigen for early pregnancy test and contraceptive vaccine |
| US4310455A (en) * | 1979-04-17 | 1982-01-12 | Research Corporation | Antigen for early pregnancy test and contraceptive vaccine |
| CA1239346A (en) * | 1985-06-04 | 1988-07-19 | Gursaran P. Talwar | Birth control vaccine |
| FR2832066A1 (fr) * | 2001-11-14 | 2003-05-16 | Agronomique Inst Nat Rech | Compositions vaccinales contraceptives comprenant un peptide ou un ensemble de peptides codes par tout ou partie de l'exon 1 d'un recepteur de la fsh |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA903671A (en) * | 1972-06-27 | J. Lewis Andrew | Soluble cancer antigens coupled to foreign proteins | |
| DE1467782A1 (de) * | 1963-07-17 | 1968-12-12 | Behringwerke Ag | Verfahren zur Herstellung von kuenstlichen Antigenen |
| US3317400A (en) * | 1964-11-23 | 1967-05-02 | Upjohn Co | Enzymatic modification of bovine growth hormone by proteolytic streptomycete cell extracts |
| GB1393965A (en) * | 1971-05-05 | 1975-05-14 | Ortho Pharma Corp | Vaccine and method for inducing infertility in a male animal |
-
1974
- 1974-05-03 CH CH604874A patent/CH622426A5/de not_active IP Right Cessation
- 1974-05-06 CA CA199,003A patent/CA1057742A/en not_active Expired
- 1974-05-07 GB GB2001874A patent/GB1473601A/en not_active Expired
- 1974-05-07 IL IL44779A patent/IL44779A/en unknown
- 1974-05-07 JP JP49051079A patent/JPS623128B2/ja not_active Expired
- 1974-05-07 NZ NZ174192A patent/NZ174192A/en unknown
- 1974-05-07 NL NL7406098A patent/NL7406098A/xx not_active Application Discontinuation
- 1974-05-07 PL PL1974170881A patent/PL97318B1/pl unknown
- 1974-05-07 IE IE967/74A patent/IE42002B1/en unknown
- 1974-05-07 DD DD178336A patent/DD113919A5/xx unknown
- 1974-05-07 SE SE7406096A patent/SE7406096L/xx unknown
- 1974-05-07 DE DE2421943A patent/DE2421943A1/de active Granted
- 1974-05-07 FR FR7415780A patent/FR2228477B1/fr not_active Expired
- 1974-05-07 AU AU68695/74A patent/AU524925B2/en not_active Expired
- 1974-05-07 AT AT377074A patent/AT356263B/de not_active IP Right Cessation
-
1980
- 1980-08-07 HK HK412/80A patent/HK41280A/xx unknown
-
1981
- 1981-12-30 MY MY128/81A patent/MY8100128A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NL7406098A (xx) | 1974-11-11 |
| DE2421943C2 (xx) | 1989-10-26 |
| FR2228477B1 (xx) | 1977-07-01 |
| AU524925B2 (en) | 1982-10-14 |
| GB1473601A (en) | 1977-05-18 |
| HK41280A (en) | 1980-08-15 |
| JPS5069221A (xx) | 1975-06-10 |
| SE7406096L (sv) | 1975-01-31 |
| PL97318B1 (pl) | 1978-02-28 |
| DE2421943A1 (de) | 1974-11-28 |
| IL44779A (en) | 1977-10-31 |
| IE42002B1 (en) | 1980-05-21 |
| AT356263B (de) | 1980-04-25 |
| IE42002L (en) | 1974-11-07 |
| MY8100128A (en) | 1981-12-31 |
| IL44779A0 (en) | 1974-07-31 |
| CA1057742A (en) | 1979-07-03 |
| NZ174192A (en) | 1985-02-28 |
| DD113919A5 (de) | 1975-07-05 |
| AU6869574A (en) | 1975-11-13 |
| ATA377074A (de) | 1979-09-15 |
| JPS623128B2 (xx) | 1987-01-23 |
| FR2228477A1 (xx) | 1974-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4161519A (en) | Process for preparing an antipregnancy vaccine | |
| US4713366A (en) | Antigenic modification of polypeptides | |
| US4855285A (en) | Antigenic modification of polypeptides | |
| US4201770A (en) | Antigenic modification of polypeptides | |
| US4384995A (en) | Antigenic modification of polypeptides | |
| US4691006A (en) | Antigenic modification of polypeptides | |
| US4767842A (en) | Antigenic modification of polypeptides | |
| EP0309863B1 (de) | Mittel und Verfahren zur Auslösung einer Immunantwort auf GnRH und Immunsterilisation von Säugern | |
| CH622426A5 (en) | Contraceptive composition | |
| US5006334A (en) | Antigenic modification of polypeptides | |
| US4762913A (en) | Antigenic modification of polypeptides | |
| DE69535260T2 (de) | Verwendung eines nicht-neutralisierenden Antikörpers spezifisch für die beta-Untereinheit von luteinisierendem Hormon zur Erhöhung der Fertilität | |
| US4966888A (en) | hCG-hLH receptor and hCG-hLH receptor-hCG complex as antigens, antibodies thereto and contraceptive vaccine | |
| DE3236264A1 (de) | Verfahren zur gewinnung von relaxin | |
| US5698201A (en) | Method for treatment of antigenically modified polypeptides | |
| Das et al. | Investigations on the ability of antisera produced by Pr-β-hCG-TT to neutralize the biological activity of hCG | |
| US6096318A (en) | Antigenically modified HCG polypeptides | |
| US6217881B1 (en) | Antigenic modification of HCG polypeptides | |
| EP0001443B1 (de) | Mittel zur Konzeptionsverhütung und Schwangerschaftsunterbrechung bei Primaten und Verfahren zu ihrer Herstellung | |
| NZ196125A (en) | Increasing fecundity of sheep or goats | |
| DE2646223C2 (xx) | ||
| Jeffcoate et al. | Effect of active immunisation of ewes against synthetic luteinising hormone releasing hormone | |
| CA1085383A (en) | Antigenic modification of polypeptides | |
| US6146633A (en) | Method for treatment of antigenically modified polypeptides | |
| US6716428B1 (en) | Antigenic modification of polypeptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |